Management Strategies for BTKi-Related CVAEs in CLL

Author(s):

Catherine C. Coombs, MDBita Fakhri, MD, MPH

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features

EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting

EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL

EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL

EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

EP: 9.Expert Insights for Long-Term Treatment Planning in CLL

EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy

EP: 11.Navigating 2L Treatment Options in CLL

EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

Now Viewing

EP: 13.Management Strategies for BTKi-Related CVAEs in CLL

EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis

EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

What is your general approach in managing newly acquired or worsening HTN or treatment-related AFib in patients receiving treatment with BTKi inhibitors?
- How do you approach treatment management in these clinical scenarios?
- When do you involve cardiology?
- When may alternative therapy be warranted?